Concepedia

Mary Uhlenhopp

MU

Statistics

Publications

8

Citations

400

H-Index

8

Active since

1995

Affiliations

Amgen (Switzerland)(Current)

Memorial Sloan Kettering Cancer Center

Royal Marsden NHS Foundation Trust

Radboud University Nijmegen

Mary Uhlenhopp is an author at Amgen (Switzerland) specializing in chemotherapy, pharmacology, and oncology.

Publications per year

1995–2017

8

Publications

8

Improving Patient Involvement in Medicines Research and Development: A Practical Roadmap

Bettina Ryll, Susanna Leto di Priolo, Mary Uhlenhopp · Therapeutic Innovation & Regulatory Science · 2017 · 143 citations

, , +9

Sequential Dose-Dense Doxorubicin, Paclitaxel, and Cyclophosphamide for Resectable High-Risk Breast Cancer: Feasibility and Efficacy

Clifford A. Hudis, Andrew D. Seidman, José Baselga et al. · Journal of Clinical Oncology · 1999 · 116 citations

, , +16

Ensuring accurate oral mucositis assessment in the European Group for Blood and Marrow Transplantation Prospective Oral Mucositis Audit

Barry Quinn, Rebecca H. Stone, Mary Uhlenhopp et al. · European Journal of Oncology Nursing · 2007 · 44 citations

, , +11

Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen.

Paul J. Hesketh, Thomas Beck, Mary Uhlenhopp et al. · Journal of Clinical Oncology · 1995 · 30 citations

, , +17

Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.

Clifford A. Hudis, A. D. Seidman, George Raptis et al. · PubMed · 1996 · 29 citations

, , +11

1–5 of 8